These products are used to assess the effectiveness of sterilisation processes
Mesa Laboratories has announced the acquisition of certain assets and liabilities of two of its European distributors by Amilabo, the company’s subsidiary located near Lyon, France. No financial details have been revealed.
These acquisitions involve Cherwell Laboratories, located in Bicester, Oxfordshire, UK and Dr Früh Control, based near Frankfurt, Germany. Both are distributors of Mesa Laboratories' biological indicator (BI) products. The two companies are engaged in other lines of business and will continue to operate as normal. Amilabo has purchased only the BI indicators and has assumed certain liabilities associated with the BI business.
Biological indicators are used to assess the effectiveness of sterilisation processes, including steam, gas (such as ethylene oxide or chlorine dioxide), hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries.
Cherwell and Früh have been distributors of Mesa’s BI products for many years, selling primarily to the pharmaceutical and medical device manufacturing markets. After a short transition period, Amilabo will conduct this business in the UK and Germany from Lyon. The company says centralised supply of BI products from France will improve the service to Mesa’s European customers by increasing product availability and reducing shipping time.
'These acquisitions continue the trend of increasing direct selling efforts in Europe that was started with the acquisition of Amilabo in April, 2014,' said John Sullivan, President and CEO of Mesa. “Selling direct allows us to grow our European BI business more effectively.'